Abstract
Immunotherapy has become an important treatment modality for recurrent or metastatic nasopharyngeal carcinoma(R/M NPC). The treatment response however appears to be lower than expected, and there are remarkable individual differences that cannot be predicted. The primary aim of this study was to explore predictive biomarkers for treatment response to immunotherapy in R/M NPC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
